click enter text
visibl lower prefer ilmn growth benefit seri
minor tailwind pharma partnership materi tailwind
genom england guid assum anoth year good fortun
popul sequenc program clinic partnership miss
pace falloff consumer/dtc demand ilmn luck turn
wors regard partnership popul program revenu top
tough comp natur headwind third year new product cycl
custom effici pressur translat volum growth
revenu growth see initi survey work sens
manag investor lose faith double-digit growth
trajectori mid-term agre patienc reward pt
year-end let lose sight key statist drive
sequenc growth doubl digit top gel comp
comp pressur without benefit front end wave clinic
assay revenu emerg fda/cm support
new news call china slow pressur
ilmn-specif major custom shift oper outsid
countri becom tailwind ilmn confid clinical/partnership
recoveri part reflect tmb smaller piec revenu stack
popul seq program alter structur scale
time regulatory/logist timelin optimist recal genom
england took year ramp cut array guidanc lower level
custom plan novaseq unit consum guidanc
reiter notabl pickup demand smaller lab
reiter pacbio close time guidanc cautiou ftc
comment come ep guidanc reduct near line
investor expect visibl admittedli low
lower estim price target estim go lower
top line ep
reduct primarili reflect servic array revenu reflect pop seq
dtc pressur see caus significantli alter medium-term
growth expect pt goe slightli higher target yield
lower estim exhibit
trade fundament data
upsid target
report limit sole use client wolf research pleas refer disclosur section locat end
report analyst certif import disclosur disclosur
page
result wolf model chang
page
estimate effect sale -- ngsmid-teen growth yoy sale mid teen growth vs end addtnl loss down/flat post-helixdown sg -- -- promis opex cut guid adj ebit margin -- -- -- non- increas due impact helix slightli higher ship expect slightli flat pull-through slightli higher ship expect slightli flat seq growth seq consum clinic sequenc marginsflat/downslightli sg -- -- tax system con ofset array ng system con ofset
note growth index compos
page
mnconsensusprior organ gross total oper oper incom incom incom net incom share ep bpsoper bp effect tax bpsnet price-to-earnings premium growth median price-to-earnings
exhibit organ sale segment
exhibit sequenc hardwar sale growth rel launch date new hardwar product
page
segment ebit bridg margin pacbio/m a- stock/destock- organ organ y/i hardwar sale growthsummari year vs launchng sale growth quarter rel system launch growth yeargrowth
page
yieldfcf compound-annual-growth-rate ebitda compound-annual-growth-rate ev-ebitda vs estimate ebitda compound-annual-growth-rate tool ntm price-to-earnings ratio median price-to-earnings premium growth median compound-annual-growth-rate
note figur million unless state per-shar term
page
note figur million unless state per-shar term
page
